로딩 중…
지수 로딩 중…
제이엘케이
322510· KOSDAQ· Health Care· Health Care Equipment & Services
₩5,060+1.91%
2026-09-18
Financials
Valuation Metrics
제이엘케이's Market Cap is ₩1302B. At end of 2025 it was ₩1430B. Ranked #1110 of 2,421 in KR market (top 46%), #579 of 1,640 on KOSDAQ (top 35%), #40 of 96 in Health Care Equipment & Services (top 42%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 130.17B KRW | KR#1,110/2,421 Sec#40/96 |
| Revenue | 2.72B KRW | KR#2,375/2,421 Sec#95/96 |
| Net Income | -15.13B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 69.51B KRW | KR#2,013/2,421 Sec#65/96 |
| Net Assets | 34.70B KRW | KR#2,126/2,421 Sec#75/96 |
| Employees | 83 | KR#1,786/2,421 Sec#69/96 |
| Value | ||
| P/B | 3.75x | KR#2,177/2,421 Sec#83/96 |
| P/S | 47.80x | KR#2,372/2,421 Sec#95/96 |
| Profitability | ||
| ROE | -43.58% | KR#2,255/2,421 Sec#82/96 |
| ROA | -21.76% | KR#2,257/2,421 Sec#79/96 |
| Op. Margin | -501.82% | KR#2,366/2,421 Sec#93/96 |
| Revenue Growth | 4.31% | KR#1,237/2,421 Sec#65/96 |
| Financial Health | ||
| Debt Ratio | 100.28% | KR#1,560/2,421 Sec#77/96 |
| Total Debt | 53.10B KRW | KR#981/2,421 Sec#24/96 |
| Cash | 4.85B KRW | KR#2,016/2,421 Sec#71/96 |
| Current Ratio | 1.85x | KR#949/2,421 Sec#57/96 |
| Performance | ||
| 1Y Return | -12.46% | KR#1,031/2,421 Sec#21/96 |
| 1M Return | 2.74% | KR#955/2,421 Sec#27/96 |
| From 52W High | -45.06% | KR#1,169/2,421 Sec#36/96 |
| 1Y MDD | -57.61% | KR#1,344/2,421 Sec#45/96 |
| Trading | ||
| Volume | 88,273 shares | KR#839/2,421 Sec#29/96 |
| Trading Value | 454.1M KRW | KR#961/2,421 Sec#31/96 |
| Foreign Own. | 1.65% | KR#1,775/2,421 Sec#67/96 |
| Per Share | ||
| EPS | -588 KRW | KR—/2,421 Sec—/96 |
| BPS | 1,349 KRW | KR#2,227/2,421 Sec#82/96 |
Company Info
Established in 2014 and listed on KOSDAQ in 2019, JLK is a medical artificial intelligence solution specialized enterprise. Leveraging AI technology, the company offers early disease diagnosis, interpretation support, and lesion detection services through the analysis of medical images such as MRI, CT, and X-Ray. JLK is commercializing MEDIHUB STROKE and Cancer Solution, and is pursuing global expansion with 76 worldwide permits and approvals. The company is headquartered in Cheongju-si, Chungcheongbuk-do.